Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2019-10-28
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of carfilzomib when given
together with melphalan and to see how well they work in treating patients with multiple
myeloma before stem cell transplant. Carfilzomib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
melphalan, work in different ways to stop the growth of cancer cells, either by killing the
cells or by stopping them from dividing. Giving carfilzomib together with melphalan may kill
more cancer cells.